Getein Biotech (603387) Stock Overview
Researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
603387 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Getein Biotech, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.41 |
| 52 Week High | CN¥9.74 |
| 52 Week Low | CN¥6.93 |
| Beta | 0.19 |
| 1 Month Change | 8.10% |
| 3 Month Change | 6.05% |
| 1 Year Change | 10.22% |
| 3 Year Change | -38.93% |
| 5 Year Change | -57.07% |
| Change since IPO | 0.84% |
Recent News & Updates
Recent updates
There Is A Reason Getein Biotech, Inc's (SHSE:603387) Price Is Undemanding
Dec 23
Is Getein Biotech (SHSE:603387) A Risky Investment?
Oct 03Getein Biotech's (SHSE:603387) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Sep 10Getein Biotech (SHSE:603387) Is Due To Pay A Dividend Of CN¥0.10
Jun 07Shareholder Returns
| 603387 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.7% | 4.1% | 1.3% |
| 1Y | 10.2% | 18.2% | 26.0% |
Return vs Industry: 603387 underperformed the CN Biotechs industry which returned 18.1% over the past year.
Return vs Market: 603387 underperformed the CN Market which returned 26% over the past year.
Price Volatility
| 603387 volatility | |
|---|---|
| 603387 Average Weekly Movement | 2.1% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 2.8% |
Stable Share Price: 603387 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603387's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,947 | n/a | www.getein.com.cn |
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection of cardiac troponin I, chemiluminescence, biochemical detection, molecular detection, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, thrombosis and hemostasis, and other technical fields, covering cardiovascular, inflammation, kidney, thyroid function, hormone, glucose metabolism, tumor, blood cells, blood coagulation, and other detection fields. Its product applications include laboratory departments of medical institutions, emergency rooms, health examination center, community clinic, family personal health management, etc. The company was founded in 2002 and is headquartered in Nanjing, China.
Getein Biotech, Inc Fundamentals Summary
| 603387 fundamental statistics | |
|---|---|
| Market cap | CN¥4.27b |
| Earnings (TTM) | CN¥201.93m |
| Revenue (TTM) | CN¥1.09b |
Is 603387 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603387 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.09b |
| Cost of Revenue | CN¥338.45m |
| Gross Profit | CN¥748.91m |
| Other Expenses | CN¥546.98m |
| Earnings | CN¥201.93m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 30, 2025
| Earnings per share (EPS) | 0.40 |
| Gross Margin | 68.87% |
| Net Profit Margin | 18.57% |
| Debt/Equity Ratio | 21.5% |
How did 603387 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/18 05:42 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Getein Biotech, Inc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andy Liu | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Jiaxi Xu | Industrial Securities Co. Ltd. |
| Yin Ye | Ping An Securities Co. Ltd. |